121 related articles for article (PubMed ID: 15012722)
1. Ramipril prevents microtubular changes in proximal tubules from streptozotocin diabetic rats.
Osicka TM; Forbes JM; Thallas V; Brammar GC; Jerums G; Comper WD
Nephrology (Carlton); 2003 Aug; 8(4):205-11. PubMed ID: 15012722
[TBL] [Abstract][Full Text] [Related]
2. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.
Allen TJ; Cao Z; Youssef S; Hulthen UL; Cooper ME
Diabetes; 1997 Oct; 46(10):1612-8. PubMed ID: 9313758
[TBL] [Abstract][Full Text] [Related]
3. Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.
Castoldi G; di Gioia CR; Bombardi C; Preziuso C; Leopizzi M; Maestroni S; Corradi B; Zerbini G; Stella A
Am J Nephrol; 2013; 37(1):65-73. PubMed ID: 23327833
[TBL] [Abstract][Full Text] [Related]
4. Ramipril and aminoguanidine restore renal lysosomal processing in streptozotocin diabetic rats.
Osicka TM; Kiriazis Z; Pratt LM; Jerums G; Comper WD
Diabetologia; 2001 Feb; 44(2):230-6. PubMed ID: 11270681
[TBL] [Abstract][Full Text] [Related]
5. Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C.
Osicka TM; Yu Y; Panagiotopoulos S; Clavant SP; Kiriazis Z; Pike RN; Pratt LM; Russo LM; Kemp BE; Comper WD; Jerums G
Diabetes; 2000 Jan; 49(1):87-93. PubMed ID: 10615954
[TBL] [Abstract][Full Text] [Related]
6. Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats.
Mavrakanas TA; Cheva A; Kallaras K; Karkavelas G; Mironidou-Tzouveleki M
Pharmacology; 2010; 86(2):85-91. PubMed ID: 20689340
[TBL] [Abstract][Full Text] [Related]
7. Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition.
Gilbert RE; Cox A; Wu LL; Allen TJ; Hulthen UL; Jerums G; Cooper ME
Diabetes; 1998 Mar; 47(3):414-22. PubMed ID: 9519748
[TBL] [Abstract][Full Text] [Related]
8. Salt blocks the renal benefits of ramipril in diabetic hypertensive rats.
Fabris B; Jackson B; Johnston CI
Hypertension; 1991 Apr; 17(4):497-503. PubMed ID: 1826492
[TBL] [Abstract][Full Text] [Related]
9. Diabetic vascular hypertrophy and albuminuria: effect of angiotensin converting enzyme inhibition.
Allen TJ; Hulthen UL; Rumble JR; Jasik M; Cooper ME
J Diabetes Complications; 1995; 9(4):318-22. PubMed ID: 8573756
[TBL] [Abstract][Full Text] [Related]
10. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
[TBL] [Abstract][Full Text] [Related]
11. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy.
Gross ML; El-Shakmak A; Szábó A; Koch A; Kuhlmann A; Münter K; Ritz E; Amann K
Diabetologia; 2003 Jun; 46(6):856-68. PubMed ID: 12802493
[TBL] [Abstract][Full Text] [Related]
12. Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery.
Osicka TM; Yu Y; Lee V; Panagiotopoulos S; Kemp BE; Jerums G
Clin Sci (Lond); 2001 Mar; 100(3):249-57. PubMed ID: 11222110
[TBL] [Abstract][Full Text] [Related]
13. Prevention of early glomerulopathy with tolrestat in the streptozotocin-induced diabetic rat.
Donnelly SM; Zhou XP; Huang JT; Whiteside CI
Biochem Cell Biol; 1996; 74(3):355-62. PubMed ID: 8883841
[TBL] [Abstract][Full Text] [Related]
14. Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy.
Thallas-Bonke V; Coughlan MT; Bach LA; Cooper ME; Forbes JM
Am J Nephrol; 2010; 32(1):73-82. PubMed ID: 20551625
[TBL] [Abstract][Full Text] [Related]
15. Ramipril reduces albuminuria in diabetic rats fed a high protein diet.
O'Brien RC; Cooper ME; Allen TJ; Jerums G
Clin Exp Pharmacol Physiol; 1989 Aug; 16(8):675-80. PubMed ID: 2529067
[TBL] [Abstract][Full Text] [Related]
16. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade.
Mifsud SA; Allen TJ; Bertram JF; Hulthen UL; Kelly DJ; Cooper ME; Wilkinson-Berka JL; Gilbert RE
Diabetologia; 2001 Jul; 44(7):878-82. PubMed ID: 11508273
[TBL] [Abstract][Full Text] [Related]
17. Impaired tubular uptake explains albuminuria in early diabetic nephropathy.
Russo LM; Sandoval RM; Campos SB; Molitoris BA; Comper WD; Brown D
J Am Soc Nephrol; 2009 Mar; 20(3):489-94. PubMed ID: 19118149
[TBL] [Abstract][Full Text] [Related]
18. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy.
Wang S; Chen Q; Simon TC; Strebeck F; Chaudhary L; Morrissey J; Liapis H; Klahr S; Hruska KA
Kidney Int; 2003 Jun; 63(6):2037-49. PubMed ID: 12753291
[TBL] [Abstract][Full Text] [Related]
19. Reduced cortical renal GLUT1 expression induced by angiotensin-converting enzyme inhibition in diabetic spontaneously hypertensive rats.
Souza MS; Machado UF; Okamoto M; Bertoluci MC; Ponpermeyer C; Leguisamo N; Azambuja F; Irigoyen MC; Schaan BD
Braz J Med Biol Res; 2008 Nov; 41(11):960-8. PubMed ID: 19099149
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor.
Gilbert RE; Huang Q; Thai K; Advani SL; Lee K; Yuen DA; Connelly KA; Advani A
Kidney Int; 2011 Jun; 79(12):1312-21. PubMed ID: 21389970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
